Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Emmanuel Abate reveals how Cytiva are making cell therapy manufacturing faster, greener, and fit for the future.
Hydrostor’s CEO explains how revolutionizing an old technology is helping to create a cheaper and more sustainable energy grid.
Antti Vihavainen reveals the science, standards, and momentum behind the global carbon removal market.
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
A digital community for clothing repairs has high hopes to upskill consumers worldwide and trigger an upcycle revolution.
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
Blood tests for cancer are here, and Guardant Health is leading the charge.
Neil Warma explains how Mongoose Bio is pioneering TCR-T therapies that may last longer, tackle more cancers, and require less from patients.